Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Heng Lin; Lina Li; Shuimei Luo; Sijing Zhou; Ruifen Shen; Haitao Yang; Huijuan Chen; Xianhe Xie

doi:10.18632/oncotarget.13588

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Heng Lin, Lina Li, Shuimei Luo, Sijing Zhou, Ruifen Shen, Haitao Yang, Huijuan Chen and Xianhe Xie _

PDF | HTML | How to cite

Oncotarget. 2017; 8:1141-1155. https://doi.org/10.18632/oncotarget.13588

Metrics: PDF 2449 views | HTML 1880 views | ?

Abstract

Heng Lin1,2,*, Lina Li1,*, Shuimei Luo1, Sijing Zhou1, Ruifen Shen1, Haitao Yang1, Huijuan Chen1, Xianhe Xie1

1Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China

2Department of Oncology, Fuzhou Pulmonary Hospital, Fuzhou, Fujian, China

*These authors have contributed equally to this work

Correspondence to:

Xianhe Xie, email: [email protected]

Keywords: angiogenesis inhibitors, chemotherapy, targeted therapy, small-cell lung cancer, meta-analysis

Received: July 02, 2016 Accepted: November 09, 2016 Published: November 25, 2016

ABSTRACT

Objective: The purpose of this study was to investigate the efficacy and safety of angiogenesis inhibitors for small-cell lung cancer (SCLC).

Methods: Totally, 16 controlled trials (1898 cases) involving angiogenesis inhibitors plus chemotherapy (ACT group) versus chemotherapy alone group (CT group) were identified from PubMed, EMBASE, Cochrane Library and Wanfang Data before March 2016.

Results: Compared with CT group, ACT group obtained a significant benefit on objective response rate (ORR) (RR = 1.34; 95% CI = 1.19-1.51; P < 0.00001) and a trend of prolonging progression-free survival (PFS) (HR = 0.86; 95% CI = 0.73-1.01; P = 0.07) without improving overall survival (OS) (HR = 1.05; 95% CI = 0.94-1.17; P = 0.36). Remarkably, subgroup analysis showed that the antibodies targeting VEGF significantly prolonged PFS (HR = 0.76; 95% CI = 0.64-0.90; P = 0.001). With regard to toxicity, there was no significant difference in severe adverse events (AEs, Grade≥3) between two groups except that gastrointestinal symptom, hypertension, metabolic disorders, neurology and pain were higher in ACT group.

Conclusion: Compared with chemotherapy alone, antibodies targeting VEGF plus chemotherapy significantly improved ORR and prolonged PFS with an acceptable toxicity profile for patients with SCLC. Therefore, angiogenesis inhibitors, especially antibodies targeting VEGF, combining with chemotherapy may be a potential promising strategy in managing SCLC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13588

Publication Alerts

Research Papers:

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Abstract